Astrotech Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2014, with comparative results for fiscal 2013. The filing is a 2014 annual report, not a 2012 fourth-quarter report.
Business context
Before a major post-year-end divestiture, Astrotech operated Astrotech Space Operations (ASO), providing satellite processing and launch-support services, and Spacetech, focused on 1st Detect’s miniature mass spectrometers and Astrogenetix’s microgravity vaccine research. ASO generated 99% of fiscal 2014 revenue. On August 22, 2014, the company sold substantially all ASO assets to Lockheed Martin for $61.0 million, subject to $1.8 million working-capital and $6.1 million indemnity holdbacks. The company described the sale as a strategic move to focus on Spacetech.
Financial results and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $16.423 million | $23.995 million |
| Gross profit / margin | $5.718 million / 35% | $8.311 million / 35% |
| Operating expenses | $11.398 million | $8.870 million |
| Operating loss | $5.680 million | $0.559 million |
| Consolidated net loss | $5.868 million | $0.723 million |
| Net loss attributable to Astrotech | $4.960 million; $0.25 per share | $0.185 million; $0.01 per share |
| Cash used in operating activities | $0.552 million | $2.902 million |
Revenue fell 31.6%, primarily because of lower mission and project-related activity. Gross margin was broadly stable, but higher operating expenses—especially SG&A and Spacetech investment—drove the larger loss. Fiscal 2014 SG&A included increased incentive compensation and approximately $0.6 million of incremental stock-option compensation after vesting was accelerated by the share-price threshold.
At June 30, 2014, cash was $3.831 million, working capital was approximately negative $4.4 million, total assets were $40.782 million, and stockholders’ equity was $30.300 million. The $5.655 million term loan was classified as current after covenant breaches tied to a delayed customer mission. After the ASO sale, the company paid off the loan on August 22, 2014 and settled the Texas Emerging Technology Fund award for $2.3 million on August 27. Management stated that sale proceeds and available funds were sufficient for expected operating and capital needs over the next fiscal year.
Changes, outlook, risks and unusual items
- ASO revenue declined from $23.862 million to $16.293 million; segment net income declined from $3.121 million to $1.606 million. Spacetech revenue remained approximately $0.1 million, while its attributable net loss increased to $6.566 million from $3.306 million as resources shifted toward 1st Detect.
- The ASO divestiture materially changes the company’s business and revenue base after year-end. The $6.1 million indemnity holdback was escrowed through February 2016; final working-capital settlement remained pending.
- Management provided no quantitative revenue or earnings guidance. Its strategy is to fund Spacetech, particularly 1st Detect’s product and channel-partner development. Astrogenetix was concentrating on an FDA Investigational New Drug application for a Salmonella vaccine; additional NASA flights depended on successful filing.
- Key risks include commercial adoption and financing needs for early-stage products, dependence on government funding and launch schedules, customer concentration, competition, technology-development milestones, and access to space. Three customers represented approximately 46%, 22% and 17% of FY2014 revenue; U.S. Government contracts or subcontracts represented 46%.
- The company amended bank covenants after a customer mission was deferred, but still failed its debt-service-coverage and tangible-net-worth covenants in fiscal Q3 and Q4. It also reported a full valuation allowance against net deferred tax assets. Management said no Texas award default had occurred as of June 30, 2014.
- A former CFO’s contract lawsuit was settled, and a shareholder derivative suit was dismissed. A separate Florida foreclosure action named Astrotech because it held an inferior lien; no monetary relief was sought from the company. The filing states disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal controls.
Important facts for investors to verify
- Cash actually received from the ASO sale after both holdbacks, and the final working-capital adjustment.
- Any indemnity claims or release of the $6.1 million escrow, and the ultimate use of sale proceeds after the debt and Texas award settlements.
- Post-sale cash burn, financing requirements, and the remaining operating costs and liabilities associated with the ASO disposal.
- Commercial sales, customer conversions and recurring revenue for 1st Detect, and progress toward the Salmonella IND filing and any related NASA funding or flights.
- Whether customer concentration, government-contract exposure and mission timing continue to affect revenue and liquidity.